SCHEMBL2194436

SCHEMBL2194436

Brc1ccc(CN(I)I)cc1.Cn1nc(Cc2ccccc2)[nH]c1=[Pt]

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.34
FPR1 P21462 1/20 0.32
FPR2 P25090 1/20 0.32
POLB P06746 1/20 0.32
PYCR1 P32322 1/20 0.32
TSHR P16473 1/20 0.32
HTT P42858 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
DRD2 P14416 1/20 0.31
DRD3 P35462 1/20 0.31
PDE3B Q13370 2/20 0.31
PDE3A Q14432 2/20 0.31
TYMP P19971 1/20 0.31
GAA P10253 2/20 0.30
MEN1 O00255 1/20 0.30
GALR3 O60755 1/20 0.30
MAPT P10636 1/20 0.30
NPY1R P25929 1/20 0.30
STAT3 P40763 1/20 0.30
NPY2R P49146 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2195930 0.93 GAA (0.34) TSHRGAAMAPTKMT2APNP
SCHEMBL2199132 0.91 CYP2C19 (0.36) POLBHTTGAAMEN1MAPT
SCHEMBL2196817 0.88 NR1H2 (0.36) POLBGAAMAPTNR1H2NR1H3
SCHEMBL2196864 0.88 CACNA1G (0.36) L3MBTL1KMT2A
SCHEMBL2194207 0.87 PDE5A (0.34) PYCR1TYMPALKBH3
SCHEMBL2194836 0.85 PDE2A (0.35) POLBTYMPMEN1KMT2AALKBH3
SCHEMBL2195103 0.85 PDE2A (0.35) POLBTYMPMEN1KMT2AALKBH3
SCHEMBL2196435 0.85 MEN1 (0.39) FPR1FPR2POLBHTTGAA
SCHEMBL2193608 0.82 MAPK13 (0.36) BCHEPYCR1TSHRHTTL3MBTL1
SCHEMBL2196384 0.80 PDE5A (0.36) PYCR1TYMPALKBH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 BCHE 2321/4885FPR1 1774/4885FPR2 1339/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 BCHE 2321/4885FPR1 1774/4885FPR2 1339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.